Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 45, Issue 2, pp 177–181 | Cite as

Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

  • Ofer Merimsky
  • Isaac Meller
  • Gidon Flusser
  • Yehuda Kollender
  • Josephine Issakov
  • Miriam Weil-Ben-Arush
  • Eyal Fenig
  • Gad Neuman
  • Dov Sapir
  • Shmuel Ariad
  • Moshe Inbar
  • for the Israeli Soft Tissue and Bone Sarcoma Treatment Groups
CLINICAL TRIAL REPORT

Abstract

Purpose: To assess the efficacy of gemcitabine in patients with a variety of sarcomas that have failed to respond or escaped Adriamycin- and ifosfamide-based chemotherapy. Patients and methods: A group of 18 symptomatic heavily pretreated patients with sarcomas of bone or soft tissue received one induction course of gemcitabine at a dose of 1000 mg/m2 per week for 7 consecutive weeks, followed by 1 week rest. Response to the induction course was assessed by interview and by repeated ancillary tests. If no progression was observed, maintenance by gemcitabine 1000 mg/m2 per week for 3 weeks every 28 days was given until failure was clinically or radiologically evident. Results: A total of 51 cycles of gemcitabine were given including 18 cycles of induction. A mean of 3.6 postinduction cycles were given to nine patients. The treatment was well tolerated by the patients. One partial response (leiomyosarcoma) and one minimal response (angiosarcoma) were observed, yielding a true objective response rate of 5.5%. An additional six patients achieved stabilization of disease (chondrosarcoma and osteosarcoma), yielding an overall progression-free rate of 44%. The median time to progression was more than 27 weeks. Clinical benefit response was observed only in those who also achieved a progression-free state. Conclusion: Gemcitabine was found to be effective in achieving stabilization and even a minimal response of soft tissue or bone sarcoma refractory to standard chemotherapy.

Key words Gemcitabine Soft tissue sarcoma Bone sarcoma Angiosarcoma Leiomyosarcoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • Ofer Merimsky
    • 1
  • Isaac Meller
    • 2
  • Gidon Flusser
    • 3
  • Yehuda Kollender
    • 2
  • Josephine Issakov
    • 4
  • Miriam Weil-Ben-Arush
    • 5
  • Eyal Fenig
    • 6
  • Gad Neuman
    • 7
  • Dov Sapir
    • 8
  • Shmuel Ariad
    • 9
  • Moshe Inbar
    • 1
  • for the Israeli Soft Tissue and Bone Sarcoma Treatment Groups
  1. 1.Department of Oncology, The Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 64239, Israel e-mail: merimsky@internet-zahav.net Fax: +972-3-6974828IL
  2. 2.National Unit of Orthopedic Oncology, The Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, IsraelIL
  3. 3.Department of Radiology, The Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, IsraelIL
  4. 4.Department of Pathology, The Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, IsraelIL
  5. 5.Department of Pediatric Oncology, Rambam Medical Center, Haifa, IsraelIL
  6. 6.Department of Oncology, Rabin Medical Center, Petach-Tiqua, IsraelIL
  7. 7.Department Pediatric Oncology, Sheba Medical Center, Tel-Hashomer, IsraelIL
  8. 8.Department Oncology, Haemek Medical Center, Afula, IsraelIL
  9. 9.Department of Oncology, Soroka Medical Center, Beer-Sheva, IsraelIL

Personalised recommendations